KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Chemed (CHE) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Chemed (CHE) over the last 17 years, with Q3 2025 value amounting to -$120.2 million.

  • Chemed's Net Cash Flow fell 87278.11% to -$120.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.7 million, marking a year-over-year decrease of 26645.84%. This contributed to the annual value of -$85.6 million for FY2024, which is 14509.67% down from last year.
  • Per Chemed's latest filing, its Net Cash Flow stood at -$120.2 million for Q3 2025, which was down 87278.11% from $76.0 million recorded in Q2 2025.
  • Chemed's 5-year Net Cash Flow high stood at $101.9 million for Q2 2023, and its period low was -$120.2 million during Q3 2025.
  • In the last 5 years, Chemed's Net Cash Flow had a median value of -$1.9 million in 2022 and averaged -$1.7 million.
  • As far as peak fluctuations go, Chemed's Net Cash Flow tumbled by 127651.31% in 2021, and later skyrocketed by 149790.46% in 2022.
  • Over the past 5 years, Chemed's Net Cash Flow (Quarter) stood at $4.2 million in 2021, then soared by 1497.9% to $66.3 million in 2022, then skyrocketed by 36.87% to $90.8 million in 2023, then crashed by 166.18% to -$60.1 million in 2024, then crashed by 99.92% to -$120.2 million in 2025.
  • Its Net Cash Flow was -$120.2 million in Q3 2025, compared to $76.0 million in Q2 2025 and -$4.5 million in Q1 2025.